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Key summary points
Aim To explore the link between polypharmacy, psychotropic medications, and falls risk in a cohort of UK care home 
residents.
Findings Polypharmacy and psychotropic drugs are predictive of falls in UK care home residents.
Message Deprescribing interventions relating to psychotropic drugs should continue to be encouraged.
Abstract
Purpose Falls and polypharmacy are both common in care home residents. Deprescribing of medications in residents with 
increased falls risk is encouraged. Psychotropic medications are known to increase falls risk in older adults. These drugs 
are often used in care home residents for depression, anxiety, and behavioural and psychological symptoms of dementia. 
However, a few studies have explored the link between polypharmacy, psychotropic medications, and falls risk in care home 
residents.
Methods This was a prospective cohort study of residents from 84 UK care homes. Data were collected from residents’ care 
records and medication administration records. Age, diagnoses, gender, number of medications, and number of psychotropic 
medications were collected at baseline and residents were monitored over three months for occurrence of falls. Logistic 
regression models were used to assess the effect of multiple medications and psychotropic medication on falls whilst adjust-
ing for confounders.
Results Of the 1655 participants, mean age 85 (SD 8.9) years, 67.9% female, 519 (31%) fell in 3 months. Both the total 
number of regular drugs prescribed and taking ≥ 1 regular psychotropic medication were independent risk factors for fall-
ing (adjusted odds ratio (OR) 1.06 (95% CI 1.03–1.09, p < 0.01) and 1.39 (95% CI 1.10–1.76, p < 0.01), respectively). The risk 
of falls was higher in those taking antidepressants (p < 0.01) and benzodiazepines (p < 0.01) but not antipsychotics (p > 0.05).
Conclusion In UK care homes, number of medications and psychotropic medications (particularly antidepressants and ben-
zodiazepines) predicted falls. This information can be used to inform prescribing and deprescribing decisions.
Keywords Residential facilities · Accidental falls · Polypharmacy · Psychotropic medications
Introduction
Falls are associated with polypharmacy and psychotropic 
drug use. Taking four or more medications is associated with 
increased fall rates by 18% in those over the age of 60 [1]. 
Older people living at home who take psychotropic drugs 
are up to 1.62 times more likely to fall [2]. These associa-
tions are often used to justify routine medication reviews and 
deprescribing in older people at risk of falls [3].
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Falls incidence in older people living in care homes is 
three times that of those living at home. Contributors include 
physical frailty, cognitive impairment, comorbidities, and 
polypharmacy, which are all more prevalent in care homes 
[4]. Psychotropic medications (including, antipsychotics, 
anxiolytics, hypnotics, and antidepressants) are more com-
monly prescribed for care home residents because of under-
lying dementia, depression, and behavioural symptoms [5, 
6]. The average UK care home resident takes eight medi-
cations, which could place them at increased risk of falls, 
although association between falls and medications in this 
group has been less widely studied than community popula-
tions [2, 7].
Polypharmacy and psychotropic drug use might be 
expected to show a similar association with falls in care 
home and community-dwelling populations. However, the 
risk factors for falls in care homes may differ from the wider 
population, and the association between falls, polypharmacy, 
and psychotropic drug use may differ accordingly. Doctors 
may be tempted to prescribe psychotropic medications to 
reduce behaviours such as wandering, which are felt to be 
risk factors for falls, or they may be unsure about the size 
of risk of falls associated with them. Psychotropic drug pre-
scriptions in Dutch Nursing Home residents are associated 
with a threefold increase in falls risk [8]. Dutch Nursing 
Homes are, though, organised differently from UK care 
homes and, importantly, have differing practises regarding 
physical restraint—so associations seen in one country may 
not be replicated elsewhere [9].
To provide clarity on this topic and support better clini-
cal decision-making, we examined the relationship between 
falls, polypharmacy and psychotropic drug use, using data 
from a large cluster randomised controlled trial of a multi-
factorial falls prevention programme in care homes (FinCH). 
The study objectives were to determine if polypharmacy and 
psychotropic medications increased the risk of falls in UK 
care home residents.
Methods
The Falls in Care Home (FinCH) study was a multi-centre 
cluster randomised controlled trial investigating the efficacy 
of the Guide to Action Care Home (GtACH) fall prevention 
programme. It was conducted between 2016 and 2019 in 
84 UK care homes. The full protocol has been published 
[10]. Ethical approval was provided by the Yorkshire & The 
Humber-Bradford Leeds Research Ethics Committee (REC: 
16/YH/0111). Permission to use data for the sub-analysis 
presented here was granted by the Trial Steering commit-
tee, shown in “Appendix A”. Informed consent for the trial 
was obtained from participants, or a consultee if participants 
lacked capacity.
This sub-analysis considers the baseline 3 month period 
prior to randomisation and hence before exposure to any 
study-related intervention which might have changed falls 
or medication management. Data collection took place in 
the 18 months between August 2016 and February 2018.
Data were collected from care home records on age, 
gender, and medical diagnoses. Medications were recorded 
from care home Medicine Administration Record (MAR) 
charts. Eye drops and nasal sprays were included, because 
they are often systemically absorbed and may contribute to 
drug interactions. Over-the-counter (OTC) medications were 
included. Pro re nata (PRN) medications (taken as needed) 
were analysed separately for their contribution to medication 
burden. Medical equipment and dressings, topical medica-
tions (except eye drops and nasal sprays), vaccinations, and 
dietary supplements were excluded. Medication inclusion or 
exclusion decisions were considered independently by two 
researchers to minimise error. The Anatomical Therapeutic 
Chemical (ATC) classification system was used to classify 
psychotropic drugs and create an adapted version of the clas-
sification used by Cox et al. [8]. This classification and the 
psychotropic drugs prescribed are shown in “Appendix B”. 
Polypharmacy was defined as taking five or more medica-
tions based on prior work which shows a strong association 
with falls at this level [11]. Falls incidence over the 3 month 
observation period was the outcome variable. Falls were 
defined as “an unexpected event in which the participants 
come to rest on the ground, floor, or lower level” [12]. Due 
to uncertainty associated with unwitnessed falls, if a resident 
was found on the floor, it was assumed that they had fallen. 
Falls data were collated from care home records and incident 
report forms, both of which have been previously validated 
as reliable sources [13].
Demographic, medication, and falls data for each par-
ticipant in the baseline period were imported into Micro-
soft Excel 2016. Falls without a date were excluded. Where 
medication data were affected by spelling errors, they were 
included only if an agreement was established between two 
medically trained members of the research team over which 
drug was intended.
Descriptive statistics were calculated for the total popula-
tion, fallers and non-fallers. Categorical data were expressed 
as frequencies and percentages. Histograms were used to 
determine distribution and continuous data were expressed 
as means with standard deviations (SDs) if normally dis-
tributed, or medians with interquartile ranges (IQRs) if non-
parametric. Any data identified as extreme outliers were 
removed. Odds ratios and mean differences were calculated 
to determine the significant characteristics between fallers 
and non-fallers.
A logistic regression model with the dichotomous 
dependent variable of faller or non-faller and the continu-
ous predictor variable of number of drugs (as a measure of 
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polypharmacy) was fitted. Demographic data were included 
as predictors in the model to control for possible confound-
ers. A further binary logistic regression was performed using 
the same dichotomous dependent variable and adding in 
whether the participant was on psychotropic drug(s) or not 
as a categorical predictor variable. Each regression analysis 
was performed twice, with and without PRN drugs. A p 
value < 0.05 was considered significant. All statistical analy-
ses were carried out using Statistical Package for Social Sci-
ences (SPSS, version 24.0, IBM Corporation, Armonk, NY).
Results
Study population
Data from 1655 participants were analysed, with character-
istics summarised in Table 1. The mean age of participants 
was 85 years (SD 8.9). Approximately two-thirds of the 
population were female. Dementia was the most prevalent 
diagnosis with 1112 residents (67%) diagnosed with the 
condition.
A total of 3671 (26%) medications listed in the MAR 
were removed due to exclusion criteria and 14 due to inde-
cipherable spelling errors, leaving 10,226 medications used 
by the population which were then analysed. The median 
number of drugs prescribed per resident was 6 (IQR 3–9) 
Table 1  Characteristics of study 
population, showing the total 
population and the differences 
between fallers and non-fallers
Values are Mean (SD), Median (IQR) or Number (Proportion)
a Mean difference calculated for continuous data
b In calculating coronary heart disease percentages n = 1654 (Total population) and n = 1135 (Non-Fallers) 
to account for missing data for one resident who did not fall
c Polypharmacy = ≥ 5 drugs
Total population Fallers Non-fallers Univariate analysis P value
N = 1655 N = 519 N = 1136 OR (95% CI)
Age 85.0 (SD 8.9) 85.8 (SD 8.1) 84.7 (SD 9.2) 1.10 (0.18–2.02)a 0.019
Gender
 Female 1,123 (67.9%) 329 (63.4%) 794 (69.9%)
 Male 532 (32.1%) 190 (36.6%) 342 (30.1%) 1.34 (1.08–1.67) 0.008
Diagnoses
 Dementia 1112 (67.2%) 386 (74.4%) 726 (63.9%) 1.64 (1.30–2.06) < 0.001
 Diabetes 321 (19.4%) 98 (18.9%) 223 (19.6%) 0.95 (0.73–1.24) 0.721
 Stroke 262 (15.8%) 81 (15.6%) 181 (15.9%) 0.97 (0.73–1.30) 0.866
 Coronary heart disease 235 (14.2%)b 73 (14.1%) 162 (14.3%)b 0.98 (0.73–1.32) 0.910
Number of drugs
 Without PRN 6 (IQR 3–9) 6 (IQR 4–9) 6 (IQR 3–8) <0.001
 Including PRN 7 (IQR 4–10) 8 (IQR 5–11) 7 (IQR 4–10) <0.001
Number of residents on  polypharmacyc
 Without PRN 1,024 (61.9%) 350 (67.4%) 674 (59.3%) 1.42 (1.14–1.77) 0.002
 Including PRN 1,164 (70.3%) 398 (76.7%) 766 (67.4%) 1.59 (1.25–2.02) < 0.001
Number of residents taking psychotropic drug(s)
 Without PRN 816 (49.3%) 295 (56.8%) 521 (45.9%) 1.55 (1.26–1.92) < 0.001
 Including PRN 870 (52.6%) 307 (59.2%) 563 (49.6%) 1.47 (1.19–1.82) < 0.001
Number of residents taking antidepressant(s)
 Without PRN 613 (37%) 219 (42.2%) 394 (34.7%) 1.37 (1.11–1.70) 0.003
 Including PRN 614 (37.1%) 219 (42.2%) 395 (34.8%) 1.37 (1.12–1.69) 0.004
Number of residents taking antipsychotic(s)
 Without PRN 251 (15.2%) 87 (16.8%) 164 (14.4%) 1.19 (0.90–1.59) 0.221
 Including PRN 278 (16.8%) 91 (17.5%) 187 (16.5%) 1.08 (0.82–1.42) 0.588
Number of residents taking benzodiazepine(s)
 Without PRN 207 (12.5%) 84 (16.2%) 123 (10.8%) 1.59 (1.18–2.14) 0.002
 Including PRN 329 (19.9%) 122 (23.5%) 207 (18.2%) 1.38 (1.07–1.77) 0.013
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excluding PRN. Polypharmacy (without PRN) was present 
in 1024 (62%) participants. Regular psychotropic drug pre-
scriptions were present in approximately half of the popula-
tion (49%).
Polypharmacy and falls
There were a total of 1188 falls in the population, with 519 
residents having ≥ 1 fall, in the 3 months. The first logis-
tic regression model assessed the effect of the number of 
drugs (excluding PRN drugs), adjusting for gender, age, and 
dementia (Table 2). Further control for other demographics 
had no significant effect and was removed from the model. 
The model explained between 3.1% and 4.3% of variability 
in falls outcomes.
All four predictor variables made a significant contribu-
tion to the model. For every additional drug prescribed, the 
odds of falling increased by 1.058 times, after controlling 
for the other factors mentioned above. Older residents were 
more likely to fall than their younger counterparts. Men 
were predicted to fall more than women, and residents with 
dementia were predicted to fall 75% more than those without 
dementia. In the second binary logistic regression model the 
predictor effect including PRN drugs was tested, this found 
similar results to the previous model.
Psychotropic medications and falls
816 (49.3%) residents took regular psychotropic medica-
tions. In unadjusted analysis, psychotropic medications were 
associated with falls (p < 0.001). The risk of falls was higher 
in those taking antidepressants (p < 0.01) and benzodiaz-
epines (p < 0.01) but not antipsychotics (p > 0.05).
A third binary logistic regression model assessed the 
effect of one or more psychotropic drugs excluding PRN 
drugs, and controlled for age, gender, dementia diagnosis, 
and number of drugs (Table 3). The adjusted odds ratio of 
taking one or more psychotropic drug on falls risk was 1.39 
(95% CI 1.100–1.762, p = 0.006). All variables controlled 
for showed a similar significant effect as in previous mod-
els. Likewise, the number of drugs remained a significant 
predictor.
In the final model, the predictor effect of whether a resi-
dent was on one or more psychotropic drugs including PRN 
drugs was tested, this again yielded similar results to those 
excluding PRN.
Discussion
Polypharmacy and psychotropic prescriptions were both 
prevalent in care home residents, and both were associated 
with an increased falls risk. These findings were independent 
of age, gender, and dementia diagnosis.
An important strength of this study is the large and repre-
sentative dataset of UK care home residents from the FinCH 
study trial. The age of residents in this study was similar to 
that in a previous representative cohort study on the health 
of UK care home residents [7]. The proportion of residents 
with dementia in this study is close to that reported in large 
national studies [7, 14]. Only one participant was excluded 
from this study due to missing diagnostic data. Prospective 
falls data were rigorously collected and recorded on stand-
ardised forms, reducing the probability of recall bias and 
underreporting. The use of MAR sheets, used by care home 
staff to administer drugs, provided reliable data on medica-
tions prescribed and taken. Limitations associated with the 
use of MAR sheets are that the duration of drug prescription 
cannot be ascertained from these and that drugs could have 
been changed during the three months of follow-up. It was 
not possible in our analysis to account fully for the influence 
of individual or combined comorbidities. Medical condi-
tions, for instance arthritis, may affect postural stability and 
gait more than the drugs given for them. We did not include 
functional impairment in our model; this has the potential to 
Table 2  Logistic regression analysis assessing the predictive ability 
of number of drugs excluding PRN drugs on fall outcomes in care 
home residents
Note Cox & Snell R2 = 0.031, Nagelkerke R2 = 0.043. Gender: 
1 = male, 0 = female
Predictor Odds ratio 95% CI for odds ratio P
Lower Upper
Constant 0.033 < 0.001
Age 1.021 1.008 1.034 0.001
Gender 1.405 1.120 1.762 0.003
Dementia 1.749 1.382 2.213 < 0.001
No. drugs 1.058 1.031 1.086 < 0.001
Table 3  Binary logistic regression analysis assessing the predictive 
ability of psychotropic drug(s) excluding those indicated as PRN, on 
fall outcomes in care home residents
Note Cox & Snell R2 = 0.035, Nagelkerke R2 = 0.049. Gender: 
1 = male, 0 = female
Predictor Odds ratio 95% CI for odds 
ratio
P
Lower Upper
Constant 0.027 < 0.001
Age 1.023 1.010 1.036 0.001
Gender 1.413 1.126 1.774 0.003
Dementia 1.686 1.330 2.138 < 0.001
No. drugs 1.041 1.011 1.071 0.006
Psychotropic drug(s) 1.392 1.100 1.762 0.006
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confound our analysis, for example, if antipsychotics were 
predominantly prescribed in people who were bed or chair-
bound. We also did not collate data on drug dosage and 
this might reasonably have been expected to influence the 
likelihood of falls. Dementia severity was not recorded as 
part of the FINCH study—cognitive testing was not part of 
the protocol and care home records do not record dementia 
severity well. It is, however, unlikely that dementia severity 
will have confounded our analysis, as both falls and antip-
sychotic prescribing increase as dementia progresses, and 
confounding due to dementia severity would, if anything, 
have increased the strength of association between antipsy-
chotic prescribing and falls.
The work replicates the findings of research undertaken in 
care home populations internationally that found an associa-
tion between risk of falling and the number of drugs used 
[15, 16]. Our findings show that the association between 
falls and psychotropic prescriptions is as strong in the UK 
care home population as it is in nursing homes internation-
ally and non-care home settings [3, 8, 17, 18]. In our study, 
falls were associated with antidepressants and benzodiaz-
epines, but not with antipsychotics. Both antidepressants 
and benzodiazepines have been shown to increase fall risk 
in US nursing homes, and prescribers should include falls 
risk in their decision-making process when prescribing these 
drugs [19, 20]. Our findings should not be interpreted to 
conclude that antipsychotics are safe, but simply that we did 
not observe a risk of falls associated with them; these drugs 
have other risks. Although antipsychotics were prescribed 
to a greater proportion of fallers than non-fallers, the lack of 
association between falls and antipsychotics was unexpected 
and differed from published literature [21–23]. UK national 
policies, such as the National Dementia Strategy, may have 
led to more appropriate prescribing of antipsychotics to care 
home residents with multiple falls risk factors, including 
dementia and wandering behaviours [24].
In conclusion, our findings show that care home residents 
are at increased risk of falls when they take more medica-
tions and when they take antidepressants and benzodiaz-
epines. This supports judicious deprescribing using vali-
dated tools [25, 26]. Antidepressants and benzodiazepines 
should be used only when absolutely indicated. They should 
be appropriately tapered to cessation as soon as possible. 
The verdict on antipsychotics is less clear, but the findings 
presented here are not sufficient to recommend that they are 
used with anything other than caution. Providing adequate 
training and staffing levels to support non-pharmacological 
approaches to both depression and behavioural symptoms in 
care homes seems the most rational approach. These com-
petencies are still underdeveloped in long-term care. Build-
ing them will enable more multidisciplinary approaches to 
prescribing and deprescribing, ensuring that drugs are only 
used where they can add value, and any attendant risks are 
minimised [27].
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Appendix B See Table 4.
Fig. 1  Signed data access form
European Geriatric Medicine 
1 3
Table 4  Psychotropic 
medication classification—
those highlighted in bold were 
found in the data set
Name ATC code Class Subgroup Group
Oxazepam
Lorazepam
Lormetazepam
Temazepam
Midazolam
Loprazolam
N05BA04
N05BA06
N05CD06
N05CD07
N05CD08
N05CD11
Short-acting benzodiazepines Benzodiazepines Psychotropic
Clonazepam
Diazepam
Chlordiazepoxide
Clobazam
Flurazepam
Nitrazepam
N03AE01
N05BA01
N05BA02
N05BA09
N05CD01
N05CD02
Long-acting benzodiazepines
Zopiclone
Zolpidem
Zaleplon
N05CF01
N05CF02
N05CF03
Benzodiazepine related drugs
Chlorpromazine
Levomepromazine
Promazine
Fluphenazine
Perphenazine
Prochlorperazine
Trifluoperazine
Periciazine
Haloperidol
Benperidol
Droperidol
Flupentixol
Zuclopenthixol
Pimozide
Loxapine
N05AA01
N05AA02
N05AA03
N05AB02
N05AB03
N05AB04
N05AB06
N05AC01
N05AD01
N05AD07
N05AD08
N05AF01
N05AF05
N05AG02
N05AH01
Typical antipsychotics Antipsychotics
Lurasidone
Clozapine
Olanzapine
Quetiapine
Asenapine
Sulpiride
Amisulpride
Risperidone
Aripiprazole
Paliperidone
N05AE05
N05AH02
N05AH03
N05AH04
N05AH05
N05AL01
N05AL05
N05AX08
N05AX12
N05AX13
Atypical antipsychotics
Imipramine
Clomipramine
Trimipramine
Lofepramine
Amitriptyline
Nortriptyline
Doxepin
Dosulepin
N06AA02
N06AA04
N06AA06
N06AA07
N06AA09
N06AA10
N06AA12
N06AA16
Tricyclic antidepressants Antidepressants
Fluoxetine
Citalopram
Paroxetine
Sertraline
Fluvoxamine
Escitalopram
N06AB03
N06AB04
N06AB05
N06AB06
N06AB08
N06AB10
Selective serotonin reuptake inhibitors 
(SSRIs)
Isocarboxazid
Phenelzine
Tranylcypromine
N06AF01
N06AF03
N06AF04
Monoamine oxidase inhibitors
Moclobemide
Tryptophan
Mianserin
Trazodone
Minaprine
Bifemelane
Viloxazine
Mirtazapine
Bupropion
Venlafaxine
 Reboxetine
Duloxetine
 Agomelatine 
Vortioxetine
N06AG02
N06AX02
N06AX03
N06AX05
N06AX07
N06AX08
N06AX09
N06AX11
N06AX12
N06AX16
N06AX18
N06AX21
N06AX22
N06AX26
Other antidepressants
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